Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Public Health and Surveillance

Date Submitted: Jul 5, 2022
Date Accepted: Aug 10, 2023

The final, peer-reviewed published version of this preprint can be found here:

Testing for Hepatitis C During Pregnancy Among Persons With Medicaid and Commercial Insurance: Cohort Study

Khan MA, Thompson WW, Osinubi A, Meyer WA 3rd, Kaufman HW, Armstrong PA, Foster MA, Nelson NP, Wester C

Testing for Hepatitis C During Pregnancy Among Persons With Medicaid and Commercial Insurance: Cohort Study

JMIR Public Health Surveill 2023;9:e40783

DOI: 10.2196/40783

PMID: 37756048

PMCID: 10568399

Testing for hepatitis C during pregnancy among persons with Medicaid and commercial insurance: A cohort study

  • Mohammed A. Khan; 
  • William W. Thompson; 
  • Ademola Osinubi; 
  • William A. Meyer 3rd; 
  • Harvey W. Kaufman; 
  • Paige A. Armstrong; 
  • Monique A. Foster; 
  • Noele P. Nelson; 
  • Carolyn Wester

ABSTRACT

Background:

The reported incidence of acute hepatitis C virus (HCV) infection is increasing among reproductive age persons in the United States. Infants born to pregnant persons with HCV infection are at risk for perinatal HCV acquisition. Hepatitis C testing during pregnancy was evaluated during 2015 –2019.

Objective:

We estimated hepatitis C testing rates in a large sample of patients with Medicaid and commercial insurance who gave birth during 2015–2019 and described demographic and risk-based factors associated with testing.

Methods:

Medicaid and commercial insurance claims for patients ages 15–44 years who gave birth between 2015 and 2019 were included. Birth claims were identified using procedure and diagnosis codes for vaginal or cesarean delivery. Hepatitis C testing was defined as an insurance claim during the 42 weeks before delivery. Testing rates were calculated among patients who delivered and among the subset of patients who were continuously enrolled for 42 weeks before delivery. Multivariable logistic regression was used to identify factors associated with testing.

Results:

Among 1,142,770 Medicaid patients and 1,207,132 commercially insured patients, 15.3% and 18.3% were tested for hepatitis C during pregnancy, respectively. Testing rates were 21.8% and 21.9% among continuously enrolled Medicaid and commercially insured patients, respectively. Rates increased from 2015 through 2019 among Medicaid (from 19.2% to 26.8%) and commercially insured patients (from 18.1% to 28.0%), respectively. Among Medicaid patients, non-Hispanic Black and Hispanic race/ethnicity were associated with lower odds of testing. Opioid use disorder, HIV infection, and high-risk pregnancy were associated with higher odds of testing in both Medicaid and commercially insured patients.

Conclusions:

Hepatitis C testing during pregnancy increased from 2015 through 2019 among patients with Medicaid and commercial insurances although tremendous opportunity for improvement remains.


 Citation

Please cite as:

Khan MA, Thompson WW, Osinubi A, Meyer WA 3rd, Kaufman HW, Armstrong PA, Foster MA, Nelson NP, Wester C

Testing for Hepatitis C During Pregnancy Among Persons With Medicaid and Commercial Insurance: Cohort Study

JMIR Public Health Surveill 2023;9:e40783

DOI: 10.2196/40783

PMID: 37756048

PMCID: 10568399

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.